Form 4: CSTL CFO Sells Shares Under 10b5-1 Plan

Castle Biosciences CFO Frank Stokes sold 5,388 shares of common stock for a weighted-average price of $35.08 per share, pursuant to a pre-arranged 10b5-1 plan.

Summary

• Frank Stokes, Chief Financial Officer of Castle Biosciences Inc. (CSTL), sold 5,388 shares of common stock.
• The transaction occurred on November 11, 2025.
• The weighted-average sale price was $35.08 per share, with trades executed in multiple prices ranging from $34.44 to $35.37.
• The sale was made pursuant to a Rule 10b5-1 plan adopted by Mr. Stokes on August 12, 2025.
• Following this transaction, Mr. Stokes directly beneficially owns 43,328 shares of Castle Biosciences common stock.

Sentiment

Score: 5

Explanation: The transaction is a pre-scheduled insider sale under a 10b5-1 plan, which typically indicates a neutral sentiment as it's not driven by immediate market reactions or new company developments.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This Form 4 filing reports a routine insider transaction under a pre-arranged plan, which is a common practice across industries for executives to manage personal finances and diversify holdings. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may note the reduction in direct ownership by a key executive, though the pre-arranged 10b5-1 plan mitigates concerns about immediate negative sentiment or a lack of confidence in the company's future.

Key Dates

Recommendation

The sale by the Chief Financial Officer was conducted under a pre-arranged Rule 10b5-1 plan, which is a common practice for executives to manage personal finances without implying a change in their outlook on the company's prospects. This type of transaction is generally considered neutral and does not typically warrant a change in investment recommendation based solely on this filing.

Keywords

Castle Biosciences, CSTL, Frank Stokes, Insider Sale, Form 4, 10b5-1 Plan, Chief Financial Officer, Stock Transaction